GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darr. Fertigspritze/Fertigpen

Health · Germany government procurement

Closed September 30, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), via an open-house model for the active ingredient epinephrine (ATC code according to the WHO: C01CA24) in pre-filled syringes/pre-filled pens

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedAugust 01, 2025
Procurement stageActive solicitation
ClosedSeptember 30, 2026
StatusClosed — no longer accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Colchicin, ATC M04AC01 für die Zeit 01.08.2025 - 31.07.2027 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient tezepelumab, ATC R03DX11, for the period 01.06.2025 - 31.05.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Somatropin, ATC H01AC01 für die Zeit 01.07.2025 - 30.06.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Baricitinib, (OBO) ATC L04AA37 für die Zeit 01.02.2025 - 31.01.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol und Fluticason, ATC R03AK11 für die Zeit 01.06.2025 - 31.05.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lanreotid, ATC H01CB03 für die Zeit 01.07.2025 - 30.06.2026 (zzgl. Verlängerungsoption 1x 12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Erythropoietin, ATC B03XA01 für die Zeit 01.06.2025 - 31.05.2027 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Eisen (parenterale Zubereitungen), ATC B03AC07 f. d. Z. 01.11.25-31.10.27 (zzgl.Verlängerungsoption 1x12 Mon)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.